6-fluoro-1-methyl-3-(piperidin-4-yl)-1H-indazole | 161557-63-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 英文名称: 6-fluoro-1-methyl-3-(piperidin-4-yl)-1H-indazole
• 英文别名: 4-(6-fluoro-1-methyl-1H-indazol-3-yl)-piperidine；6-fluoro-1-methyl-3-(4-piperidinyl)-1H-indazole；6-fluoro-1-methyl-3-piperidin-4-ylindazole
• CAS: 161557-63-7
• 化学式: C₁₃H₁₆FN₃
• 分子量: 233.289
• InChiKey: UYHMFEUGBDQNAM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  29.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6-fluoro-1-methyl-3-(piperidin-4-yl)-1H-indazole 在 methyloxirane 作用下， 以 乙腈 为溶剂， 以600 mg (23%)的产率得到1-(2-hydroxyprop-1-yl)-4-(6-fluoro-1-methyl-1H-indazol-3-yl)piperidine
  参考文献：
  名称：

  Piperidine derivatives

  摘要：

  Piperidine衍生物的化学式为##STR1##其中A是直链或支链烷基，烷氧基烷基或烯基；X是O或NH；Y是O，S，NH，NCN或N-烷基；R.sup.1是6-氟-1,2-苯并异噁唑-3-基，6-氟-1H-吲哚-3-基，或6-氟-1-甲基-1H-吲哚-3-基；R.sup.2是烷基或苯基；R.sup.3是苯基或可选择取代的苯基，或R.sup.3是##STR2##其中Z代表一个5-或6-成员杂环；或R.sup.2和R.sup.3与氮原子一起形成融合的杂环系统；或其药用可接受盐在治疗与中枢神经系统、心血管系统或胃肠道疾病相关的适应症方面是有用的。

  公开号：

  US05478845A1

文献信息

• Condensed thiophene compound and pharmaceutical use thereof
  申请人：Yoshitomi Pharmaceutical Industries, Ltd.

  公开号：US05532240A1

  公开（公告）日：1996-07-02

  A condensed thiophene compound represented by general formula: ##STR1## or a pharmaceutically acceptable salt thereof, wherein ring S represents a thiophene ring; R.sup.1 represents hydrogen, halogen, alkyl, etc.; R.sup.2 represents hydrogen, alkyl, acyl, etc.; G represents --CH.sub.2 --, --CH(OH)--, --CO--, etc.; Q represents alkylene; T represents --N(Rb)(Rc) (wherein Rb, Rc represents each alkyl etc.; or alternatively Rb and Rc are combined together to form cyclic amino); D represents --CH.sub.2 -- or --S--; A and B represent each carbonyl or thiocarbonyl, or are null; and m and n represent each 0, 1 to 4, provided that m+n represents an integer of 4 or less. This compound is useful as an antipsychotic drug having a reduced extrapyramidal side effect.

  一种缩合噻吩化合物，其通式为：##STR1## 或其药学上可接受的盐，其中环S代表噻吩环；R1代表氢、卤素、烷基等；R2代表氢、烷基、酰基等；G代表--CH2--、--CH(OH)--、--CO--等；Q代表亚烷基；T代表--N(Rb)(Rc)（其中Rb、Rc各自代表烷基等；或者Rb和Rc结合形成环状氨基）；D代表-- --或--S--；A和B各自代表羰基或硫羰基，或者为空；m和n各自代表0、1至4，条件是m+n代表4或以下的整数。该化合物作为具有减少锥体外系副作用的抗精神病药物是有用的。
• CONDENSED THIOPHENE COMPOUND AND PHARMACEUTICAL USE THEREOF
  申请人：YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD.

  公开号：EP0596125A1

  公开（公告）日：1994-05-11

  A condensed thiophene compound represented by general formula (I) or a pharmaceutically acceptable salt thereof, wherein ring S represents a thiophene ring; R1 represents hydrogen, halogen, alkyl, etc.; R2 represents hydrogen, alkyl, acyl, etc.; G represents -CH2-, -CH(OH)-, -CO-, etc. Q represents alkylene; T represents - NH2, -NHRa (wherein Ra represents alkyl, cycloalkyl, etc.) or -NRbRc (wherein Rb and Rc represent each alkyl, etc., or alternatively Rb and Rc are combined together to form cyclic amino); D represents -CH2- or -S-; A and B represent each carbonyl or thiocarbonyl, or are null; and m and n represent each 0, 1 to 4, provided that m + n represents an integer of 4 or less. This compound is useful as an antipsychotic drug having a reduced extrapyramidal side effect or an antianxiety drug.

  通式(I)代表的缩合噻吩化合物或其药学上可接受的盐，其中环 S 代表噻吩环；R1 代表氢、卤素、烷基等；R2 代表氢、烷基、酰基等；G 代表-CH2-、-CH(OH)-、-CO-等。Q代表亚烷基；T代表-NH2、-NHRa（其中Ra代表烷基、环烷基等）或-NRbRc（其中Rb和Rc分别代表烷基等，或Rb和Rc组合在一起形成环氨基）；D代表- -或-S-；A和B分别代表羰基或硫代羰基，或为空；m和n分别代表0、1至4，条件是m+n代表4或更小的整数。这种化合物可用作具有减轻锥体外系副作用的抗精神病药物或抗焦虑药物。
• NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE
  申请人：Mitsubishi Tanabe Pharma Corporation

  公开号：EP3321256A1

  公开（公告）日：2018-05-16

  Provided is a novel low-molecular-weight compound that suppresses production of induction type MMPs, particularly MMP-9, rather than production of hemostatic type MMP-2. The present invention relates to a compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION. The compound has a selective MMP-9 production suppressive action, and is useful as a drug for the prophylaxis and/or treatment of autoimmune diseases such as rheumatoid arthritis and the like, inflammatory bowel diseases (ulcerative colitis, Crohn's disease) or osteoarthritis.

  本发明提供了一种新型低分子量化合物，它能抑制诱导型 MMP（尤其是 MMP-9）的产生，而不是抑制止血型 MMP-2 的产生。本发明涉及一种由下式（I）代表的化合物： 其中各符号如说明书所述。该化合物具有选择性抑制 MMP-9 生成的作用，可作为预防和/或治疗自身免疫性疾病（如类风湿性关节炎等）、炎症性肠病（溃疡性结肠炎、克罗恩病）或骨关节炎的药物。
• Imide derivatives and use thereof as medicine
  申请人：MITSUBISHI TANABE PHARMA CORPORATION

  公开号：US10407408B2

  公开（公告）日：2019-09-10

  Provided is a novel low-molecular-weight compound that suppresses production of induction type MMPs, particularly MMP-9, rather than production of hemostatic type MMP-2. The present invention relates to a compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION. The compound has a selective MMP-9 production suppressive action, and is useful as a drug for the prophylaxis and/or treatment of autoimmune diseases such as rheumatoid arthritis and the like, inflammatory bowel diseases (ulcerative colitis, Crohn's disease) or osteoarthritis.

  本发明提供了一种新型低分子量化合物，它能抑制诱导型 MMP（尤其是 MMP-9）的产生，而不是抑制止血型 MMP-2 的产生。本发明涉及一种由下式（I）代表的化合物： 其中各符号如说明书所述。该化合物具有选择性抑制 MMP-9 生成的作用，可作为预防和/或治疗类风湿性关节炎等自身免疫性疾病、炎症性肠病（溃疡性结肠炎、克罗恩病）或骨关节炎的药物。
• EP3321256
  申请人：——

  公开号：——

  公开（公告）日：——